What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
FSH / LH-active gonadotropin · heavily regulated
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating HMG (Human Menopausal Gonadotropin / Menotropins) through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Human Menopausal Gonadotropin, generic name Menotropins and abbreviated as HMG, is a mixed-gonadotropin biological purified from postmenopausal-female urine. The source biology works because postmenopausal physiology excretes elevated pituitary gonadotropins as a consequence of lost ovarian feedback inhibition, making the urinary source viable at commercial scale. Historically the released material carries roughly equal FSH and LH bioactivity per IU, and the resulting drug class is approved across ovulation-induction and assisted-reproductive-technology indications under brand names that include Menopur, Repronex, and a small set of biosimilars. The product's distinctive niche inside the gonadotropin category comes from carrying both FSH and LH activity in a single ampoule, which supports follicular development through the FSH arm and luteal-phase progesterone production through the LH arm in a single dispense; recombinant FSH-only alternatives like Gonal-F and Follistim require an LH-source administered separately. For compounding pharmacy and distributor buyers, Vialdyne distributes HMG only to qualified accounts holding the right import-and-dispense licensing for assisted-reproductive or compounding use in the receiving jurisdiction; every order goes through upfront compliance screening before any lot reservation is made. The 75 IU catalogue fill matches the historical Menopur ampoule format around which the clinical-practice ecosystem has built its dosing and inventory infrastructure. As with HCG, the release packet leans on biological activity (FSH IU plus LH IU per ampoule, determined by bioassay) rather than chromatographic purity alone, the urinary source means the released material is a mixed-glycoprotein population, not a single defined molecule, so RP-HPLC purity is necessary but never sufficient as the quality criterion.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: 503A / 503B compounding pharmacies and regional distributors and re-sellers.
Specifications
Certificate of Analysis
Published released-batch COAs for HMG (Human Menopausal Gonadotropin / Menotropins), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
This urine-derived gonadotropin biological carries a high regulatory burden. Purchase is restricted to qualified buyers who hold appropriate licensing in their jurisdiction, with a compliance review required for each order.
Selected literature
Frequently asked questions
Because HMG is defined by biological activity rather than a fixed mass, the released-batch COA reports FSH and LH activity in international units against the WHO gonadotropin reference standard, not simply a peptide weight. Expect the certificate to state the per-vial IU fill, the FSH:LH ratio, an in-vivo or validated in-vitro bioassay result establishing potency, and the sterility and endotoxin data appropriate to an injectable. For a urine-derived preparation, qualification files should also confirm the residual-protein and impurity controls that distinguish HMG from higher-purity fractions. Verify each of these against your monograph before dispensing.
Lyophilized gonadotropin fills are the least demanding form for storage, but the activity is heat-labile once in solution, so cold-chain discipline matters. Keep sealed vials refrigerated and protected from light, and reconstitute only at the point of use with the diluent specified on the product documentation. Add the diluent gently down the vial wall rather than forcing it onto the cake, since foaming and vigorous agitation can denature the protein and cost you potency. After reconstitution, use promptly and do not refreeze; discard any solution held beyond the labeled in-use period rather than banking partial vials.
Related peptides
